Clinical Research Directory

Inclusion Criteria: * Age: ≥18 years old. * Histologically or cytologically proven pancreatic ductal adenocarcinoma. * Multidisciplinary assessment as borderline resectable disease. * At least one measurable lesion (according to RECIST v1.1). * No prior antitumor therapy for pancreatic cancer. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 \~ 1. * The expected survival time ≥3 months. * Adequate bone marrow function as evidenced by: 1) Absolute neutrophil count (ANC) ≥1.5×10\^9/L, 2) Platelet count ≥100×10\^9/L, 3) Hemoglobin (Hb) ≥90 g/L, 4) White blood cell (WBC) ≥3.0×10\^9/L. * Adequate hepatic function as evidenced by: 1) Serum total bilirubin ≤1.5 × upper limit of normal (ULN), 2) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN * Adequate renal function as evidenced by serum creatinine (Cr)≤1.5 × ULN or creatinine clearance ≥60 mL/min. * Agree and be able to comply with the plan during the study period. Provide written informed consent before entering the study screening. Exclusion Criteria: * Any other malignancy within 5 years, with the exception of cured in-situ carcinoma or basal cell carcinoma etc. * Patients with distant metastases and/or cannot complete resection. * Active, uncontrolled bacterial, viral, or fungal infections that require systemic treatment. * Active HIV, HBV, HCV infection. * Combined with uncontrollable systemic diseases. * Presence of severe gastrointestinal disease (including active bleeding, \> grade 1 obstruction \[CTCAE v5.0\], or \> grade 1 diarrhea \[CTCAE v5.0\]). * History of allergy or hypersensitivity to drug or any of their excipients. * Patients who have chemotherapy and surgery contraindications. * Documented serum albumin ≤3 g/dL * Use of strong inhibitors or inducers of CYP3A, CYP2C8 and UGT1A1 within 14 days before the first administration. * Pregnant or breastfeeding women, or subjects of childbearing age who refuse contraception. * Participated in other trial within 30 days before the first administration. * Patients who are not suitable to participate in this trial for any reason judged by the investigator.